JP2006516976A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006516976A5 JP2006516976A5 JP2006500936A JP2006500936A JP2006516976A5 JP 2006516976 A5 JP2006516976 A5 JP 2006516976A5 JP 2006500936 A JP2006500936 A JP 2006500936A JP 2006500936 A JP2006500936 A JP 2006500936A JP 2006516976 A5 JP2006516976 A5 JP 2006516976A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- use according
- noradrenaline reuptake
- methyl
- bowel syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- -1 imidazole-5-yl - Chemical class 0.000 claims description 19
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 18
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 14
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 claims description 11
- VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 claims description 10
- 229960002430 atomoxetine Drugs 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 150000002367 halogens Chemical class 0.000 claims description 9
- 208000023505 abnormal feces Diseases 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 229950001588 ramosetron Drugs 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- GZXONPGTMHLBKQ-UTONKHPSSA-N 2,3-dihydroindol-1-yl-[(5r)-4,5,6,7-tetrahydro-3h-benzimidazol-5-yl]methanone;hydrochloride Chemical compound Cl.C1CC2=CC=CC=C2N1C(=O)[C@H]1CC(NC=N2)=C2CC1 GZXONPGTMHLBKQ-UTONKHPSSA-N 0.000 claims description 6
- 150000002431 hydrogen Chemical class 0.000 claims description 6
- YWPHCCPCQOJSGZ-LLVKDONJSA-N (2r)-2-[(2-ethoxyphenoxy)methyl]morpholine Chemical compound CCOC1=CC=CC=C1OC[C@@H]1OCCNC1 YWPHCCPCQOJSGZ-LLVKDONJSA-N 0.000 claims description 5
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 claims description 5
- 206010000060 Abdominal distension Diseases 0.000 claims description 5
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 claims description 5
- WUKZPHOXUVCQOR-UHFFFAOYSA-N N-(1-azabicyclo[2.2.2]octan-3-yl)-6-chloro-4-methyl-3-oxo-1,4-benzoxazine-8-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)C1=CC(Cl)=CC2=C1OCC(=O)N2C WUKZPHOXUVCQOR-UHFFFAOYSA-N 0.000 claims description 5
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 claims description 5
- 229960003550 alosetron Drugs 0.000 claims description 5
- FLZQKRKHLSUHOR-UHFFFAOYSA-N alosetron Chemical compound CC1=NC=N[C]1CN1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FLZQKRKHLSUHOR-UHFFFAOYSA-N 0.000 claims description 5
- 229950005951 azasetron Drugs 0.000 claims description 5
- UKTAZPQNNNJVKR-KJGYPYNMSA-N chembl2368925 Chemical compound C1=CC=C2C(C(O[C@@H]3C[C@@H]4C[C@H]5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 UKTAZPQNNNJVKR-KJGYPYNMSA-N 0.000 claims description 5
- 229960003914 desipramine Drugs 0.000 claims description 5
- 229960003413 dolasetron Drugs 0.000 claims description 5
- 229960003727 granisetron Drugs 0.000 claims description 5
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 claims description 5
- 229950007467 indisetron Drugs 0.000 claims description 5
- MHNNVDILNTUWNS-XYYAHUGASA-N indisetron Chemical group C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CN(C[C@@H](C3)N4C)C)=NNC2=C1 MHNNVDILNTUWNS-XYYAHUGASA-N 0.000 claims description 5
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 claims description 5
- 229960004090 maprotiline Drugs 0.000 claims description 5
- 229960001158 nortriptyline Drugs 0.000 claims description 5
- 229960005343 ondansetron Drugs 0.000 claims description 5
- FDXQKWSTUZCCTM-UHFFFAOYSA-N oxaprotiline Chemical compound C12=CC=CC=C2C2(CC(O)CNC)C3=CC=CC=C3C1CC2 FDXQKWSTUZCCTM-UHFFFAOYSA-N 0.000 claims description 5
- 229960002131 palonosetron Drugs 0.000 claims description 5
- CPZBLNMUGSZIPR-NVXWUHKLSA-N palonosetron Chemical compound C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 CPZBLNMUGSZIPR-NVXWUHKLSA-N 0.000 claims description 5
- NTHPAPBPFQJABD-LLVKDONJSA-N ramosetron Chemical compound C12=CC=CC=C2N(C)C=C1C(=O)[C@H]1CC(NC=N2)=C2CC1 NTHPAPBPFQJABD-LLVKDONJSA-N 0.000 claims description 5
- 229960003770 reboxetine Drugs 0.000 claims description 5
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 claims description 5
- 229960003688 tropisetron Drugs 0.000 claims description 5
- UIVFDCIXTSJXBB-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C[C]2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CN=C21 UIVFDCIXTSJXBB-ITGUQSILSA-N 0.000 claims description 5
- 229960001255 viloxazine Drugs 0.000 claims description 5
- 206010012735 Diarrhoea Diseases 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- SPKBYQZELVEOLL-QDMKHBRRSA-N chembl2111147 Chemical compound N([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C1=CC(Cl)=CC2=C1OC(C)(C)C2 SPKBYQZELVEOLL-QDMKHBRRSA-N 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 229950004681 zacopride Drugs 0.000 claims description 4
- 229950001074 zatosetron Drugs 0.000 claims description 4
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 claims description 3
- PWWDCRQZITYKDV-UHFFFAOYSA-N 1-benzyl-2-piperazin-1-ylbenzimidazole Chemical compound C1CNCCN1C1=NC2=CC=CC=C2N1CC1=CC=CC=C1 PWWDCRQZITYKDV-UHFFFAOYSA-N 0.000 claims description 3
- DBXKJORICFHAQA-UHFFFAOYSA-N 2-[(2-methylimidazol-1-yl)methyl]benzo[f]thiochromen-1-one;hydrochloride Chemical compound Cl.CC1=NC=CN1CC1=CSC2=CC=C(C=CC=C3)C3=C2C1=O DBXKJORICFHAQA-UHFFFAOYSA-N 0.000 claims description 3
- FEROPKNOYKURCJ-UHFFFAOYSA-N 4-amino-N-(1-azabicyclo[2.2.2]octan-3-yl)-5-chloro-2-methoxybenzamide Chemical compound COC1=CC(N)=C(Cl)C=C1C(=O)NC1C(CC2)CCN2C1 FEROPKNOYKURCJ-UHFFFAOYSA-N 0.000 claims description 3
- DHSSDEDRBUKTQY-UHFFFAOYSA-N 6-prop-2-enyl-4,5,7,8-tetrahydrothiazolo[4,5-d]azepin-2-amine Chemical compound C1CN(CC=C)CCC2=C1N=C(N)S2 DHSSDEDRBUKTQY-UHFFFAOYSA-N 0.000 claims description 3
- JJZXGTBGAPUCHC-PBWFPOADSA-N [(1r,5s)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 3-ethyl-2-oxobenzimidazole-1-carboxylate Chemical compound C1[C@@H](N2C)CC[C@@H]2CC1OC(=O)N1C2=CC=CC=C2N(CC)C1=O JJZXGTBGAPUCHC-PBWFPOADSA-N 0.000 claims description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 3
- 229950009727 lerisetron Drugs 0.000 claims description 3
- 229960000600 milnacipran Drugs 0.000 claims description 3
- AFOFVIBWSLOHFR-GOOCMWNKSA-N n-[(1r,5s)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]-2-oxo-3-propan-2-ylbenzimidazole-1-carboxamide Chemical compound C1[C@@H](N2C)CC[C@@H]2CC1NC(=O)N1C2=CC=CC=C2N(C(C)C)C1=O AFOFVIBWSLOHFR-GOOCMWNKSA-N 0.000 claims description 3
- KOYCUQMOCJHRJC-MLOZCBHJSA-N n-[(1s,5r)-3,9-dimethyl-3,9-diazabicyclo[3.3.1]nonan-7-yl]-1h-indazole-3-carboxamide;hydron;dichloride Chemical compound Cl.Cl.C1=CC=C2C(C(=O)NC3C[C@H]4CN(C[C@@H](C3)N4C)C)=NNC2=C1 KOYCUQMOCJHRJC-MLOZCBHJSA-N 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- 229950008418 talipexole Drugs 0.000 claims description 3
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims description 3
- 229960004688 venlafaxine Drugs 0.000 claims description 3
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 229940126569 noradrenaline reuptake inhibitor Drugs 0.000 claims 5
- 229950007654 itasetron Drugs 0.000 claims 4
- RWXRJSRJIITQAK-ZSBIGDGJSA-N itasetron Chemical compound C12=CC=CC=C2NC(=O)N1C(=O)N[C@H](C1)C[C@H]2CC[C@@H]1N2C RWXRJSRJIITQAK-ZSBIGDGJSA-N 0.000 claims 4
- 230000008485 antagonism Effects 0.000 claims 3
- MJCKISCWHDATBN-UHFFFAOYSA-N 4-amino-5-chloro-n-[(1-ethyl-4,5-dihydroimidazol-2-yl)methyl]-2-methoxybenzamide Chemical compound CCN1CCN=C1CNC(=O)C1=CC(Cl)=C(N)C=C1OC MJCKISCWHDATBN-UHFFFAOYSA-N 0.000 claims 2
- JCOJXICRPMRJPO-UHFFFAOYSA-N N-pent-3-yn-2-yloxybenzamide Chemical compound C(C1=CC=CC=C1)(=O)NOC(C#CC)C JCOJXICRPMRJPO-UHFFFAOYSA-N 0.000 claims 2
- 229950007840 bemesetron Drugs 0.000 claims 2
- MNJNPLVXBISNSX-WDNDVIMCSA-N bemesetron Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C1=CC(Cl)=CC(Cl)=C1 MNJNPLVXBISNSX-WDNDVIMCSA-N 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 229950002371 lintopride Drugs 0.000 claims 2
- 210000003097 mucus Anatomy 0.000 claims 2
- 230000000966 norepinephrine reuptake Effects 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 230000001078 anti-cholinergic effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000010006 flight Effects 0.000 claims 1
- QMEZUZOCLYUADC-UHFFFAOYSA-N hydrate;dihydrochloride Chemical compound O.Cl.Cl QMEZUZOCLYUADC-UHFFFAOYSA-N 0.000 claims 1
- 239000002966 varnish Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- YLHAMFZCYBVACR-UHFFFAOYSA-N Cl.C1=CC=CC2=C3C(=O)C=CSC3=CC=C21 Chemical compound Cl.C1=CC=CC2=C3C(=O)C=CSC3=CC=C21 YLHAMFZCYBVACR-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 201000000117 functional diarrhea Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229950003039 renzapride Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44007703P | 2003-01-13 | 2003-01-13 | |
| US49248003P | 2003-08-04 | 2003-08-04 | |
| PCT/US2004/000807 WO2004062623A2 (en) | 2003-01-13 | 2004-01-13 | Method of treating functional bowel disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011061194A Division JP2011157372A (ja) | 2003-01-13 | 2011-03-18 | 機能性腸障害を処置する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006516976A JP2006516976A (ja) | 2006-07-13 |
| JP2006516976A5 true JP2006516976A5 (https=) | 2010-11-25 |
Family
ID=32718145
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006500936A Ceased JP2006516976A (ja) | 2003-01-13 | 2004-01-13 | 機能性腸障害を処置する方法 |
| JP2011061194A Pending JP2011157372A (ja) | 2003-01-13 | 2011-03-18 | 機能性腸障害を処置する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011061194A Pending JP2011157372A (ja) | 2003-01-13 | 2011-03-18 | 機能性腸障害を処置する方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (8) | US20040147509A1 (https=) |
| EP (2) | EP2286817A3 (https=) |
| JP (2) | JP2006516976A (https=) |
| KR (1) | KR20050111318A (https=) |
| CN (1) | CN100353946C (https=) |
| AU (1) | AU2004204825B2 (https=) |
| BR (1) | BRPI0406749A (https=) |
| CA (1) | CA2512983A1 (https=) |
| MX (1) | MXPA05007381A (https=) |
| NZ (1) | NZ541008A (https=) |
| PL (1) | PL378367A1 (https=) |
| WO (1) | WO2004062623A2 (https=) |
| ZA (1) | ZA200505817B (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0216027D0 (en) * | 2002-07-10 | 2002-08-21 | Arachnova Therapeutics Ltd | New therapeutic use |
| US20040048874A1 (en) * | 2001-05-22 | 2004-03-11 | Bardsley Hazel Judith | New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine |
| JP2006516977A (ja) * | 2003-01-13 | 2006-07-13 | ダイノゲン ファーマシューティカルズ，インコーポレイテッド | 悪心、嘔吐、レッチング、またはそれらの任意の組み合わせの治療方法 |
| MXPA05007381A (es) * | 2003-01-13 | 2006-02-10 | Dynogen Pharmaceuticals Inc | Metodo para el tratamiento de transtornos funcionales del intestino. |
| JP2006522144A (ja) * | 2003-04-04 | 2006-09-28 | ダイノゲン ファーマシューティカルズ，インコーポレイテッド | 下部尿路障害の治療方法 |
| DE602006012811D1 (de) * | 2005-01-28 | 2010-04-22 | Astellas Pharma Inc | Verfahren zum screening eines therapeutischen wirkstoffs für darmirritationssyndrome |
| WO2006105117A2 (en) * | 2005-03-28 | 2006-10-05 | Dynogen Pharmaceuticals, Inc. | Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors |
| WO2007000046A1 (en) * | 2005-06-27 | 2007-01-04 | Holburn Biomedical Corporation | Methods for diagnosing functional bowel disease |
| US20070010543A1 (en) * | 2005-07-01 | 2007-01-11 | Dynogen Pharmaceuticals, Inc. | Compositions and methods for treating gastrointestinal hypomotility and associated disorders |
| US20090175933A1 (en) * | 2005-10-07 | 2009-07-09 | Colocaps Pty Ltd | Preparation for the treatment of diarrhoea |
| GB0524668D0 (en) * | 2005-12-02 | 2006-01-11 | Novartis Ag | Organic compounds |
| EP2251757B1 (en) * | 2005-12-02 | 2011-11-23 | iRobot Corporation | Coverage robot mobility |
| US20070254899A1 (en) * | 2006-03-31 | 2007-11-01 | Dynogen Pharmaceuticals, Inc. | Soluble salts of thieno[2,3-d]pyrimidine derivatives |
| TW200838534A (en) * | 2007-02-07 | 2008-10-01 | Astellas Pharma Inc | Treatment for irritable bowel syndrome |
| US20110158930A1 (en) * | 2008-08-28 | 2011-06-30 | Astellas Pharma Inc. | Method for treatment of irritable bowel syndrome |
| CN105412110B (zh) * | 2011-10-18 | 2018-05-25 | 赫尔森保健股份公司 | 奈妥匹坦和帕洛诺司琼的治疗性组合 |
| JOP20130213B1 (ar) | 2012-07-17 | 2021-08-17 | Takeda Pharmaceuticals Co | معارضات لمستقبلht3-5 |
| CA3178035A1 (en) | 2012-12-24 | 2014-07-03 | Neurogastrx, Inc. | Methods for treating gi tract disorders |
| US9844554B2 (en) | 2014-06-24 | 2017-12-19 | Neurogastrx, Inc. | Prodrugs of metopimazine |
| CA2962429C (en) * | 2014-09-29 | 2023-01-03 | Takeda Pharmaceutical Company Limited | Crystalline form of 1-(1-methyl-1h-pyrazol-4-yl)-n-((1r,5s,7s)-9-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-1h-indole-3-carboxamide |
| US10836757B1 (en) | 2020-04-02 | 2020-11-17 | Neurogastrx, Inc. | Polymorphic forms of metopimazine |
| WO2022104234A1 (en) * | 2020-11-15 | 2022-05-19 | Castor Trevor P | Methods for assaying and measuring the efficacy of anti-nausea compounds |
| CN113412817B (zh) * | 2021-05-31 | 2022-07-12 | 成都中医药大学附属医院 | 提高成模率减少死亡率的ibs-d实验动物模型方法 |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US659336A (en) * | 1900-05-25 | 1900-10-09 | Charles H Booth | Pipe-coupling. |
| JPS60146891A (ja) * | 1984-01-05 | 1985-08-02 | Mitsubishi Chem Ind Ltd | 〔２，３−ｄ〕チエノピリミジン誘導体およびその塩 |
| GB8701022D0 (en) * | 1987-01-19 | 1987-02-18 | Beecham Group Plc | Treatment |
| DE3885357T2 (de) * | 1987-06-29 | 1994-03-24 | Duphar Int Res | Anellierte Indolderivate. |
| US5007790A (en) | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
| US5530008A (en) * | 1989-04-21 | 1996-06-25 | Sandoz Ltd. | Use of 5-HT3 receptor antagonists in treating panic disorders or obsessive compulsive disorders |
| US5225407A (en) * | 1990-02-22 | 1993-07-06 | Glaxo Group Limited | 5-HT3 receptor antagonists for the treatment of autism |
| JPH06508836A (ja) * | 1991-06-26 | 1994-10-06 | セプラコア，インコーポレーテッド | 光学的に純粋なｒ（＋）オンダンセトロンを使用する嘔吐、吐き気および他の障害の治療のための方法および組成物 |
| JP2699794B2 (ja) * | 1992-03-12 | 1998-01-19 | 三菱化学株式会社 | チエノ〔３，２−ｂ〕ピリジン誘導体 |
| US5262428A (en) * | 1992-03-13 | 1993-11-16 | Wake Forest University | Biologically active tropane derivatives |
| US5582837A (en) | 1992-03-25 | 1996-12-10 | Depomed, Inc. | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
| ES2124303T3 (es) | 1992-03-25 | 1999-02-01 | Depomed Inc | Formas de dosificacion de farmacos orales de liberacion retardada a base de hidroxietilcelulosa. |
| US5434174A (en) * | 1992-07-17 | 1995-07-18 | Eli Lilly And Company | Isoxazole derivatives for the treatment of irritable bowel syndrome |
| DE4238553A1 (de) * | 1992-11-14 | 1994-05-19 | Kali Chemie Pharma Gmbh | Neue Imidazol-1-yl-Verbindungen enthaltende Arzneimittel |
| JPH0616557A (ja) * | 1992-12-21 | 1994-01-25 | Mitsubishi Kasei Corp | 脳機能障害改善剤 |
| GB9406857D0 (en) * | 1994-04-07 | 1994-06-01 | Sandoz Ltd | Improvements in or relating to organic compounds |
| MY113062A (en) * | 1994-05-10 | 2001-11-30 | The Wellcome Foundation Ltd | Amide derivatives and their therapeutic use |
| US5576317A (en) * | 1994-12-09 | 1996-11-19 | Pfizer Inc. | NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis |
| MY113429A (en) | 1995-02-28 | 2002-02-28 | Univ Temple | Controlled release tablet containing swellable polyethylene oxide |
| US7048906B2 (en) * | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
| JPH11505258A (ja) * | 1995-05-17 | 1999-05-18 | セダーシナイ メディカル センター | 小腸における消化および吸収を改善させる脂肪酸を含む組成物 |
| DK0855397T3 (da) * | 1995-07-28 | 2001-06-25 | Dainippon Pharmaceutical Co | (R)-5-brom-N-(ethyl-4-methylhexahydro-1H-1,4-diazepin-6-yl)-2-methoxy-6-methylamino-3-pyridincarboxamid, fremgangsmåde til dets fremstilling og medicinsk præparat indeholdende denne forbindelse |
| AU702594B2 (en) * | 1995-10-13 | 1999-02-25 | Duphar International Research B.V. | Process for the preparation of enantiomerically pure imidazolyl compounds |
| ES2208870T3 (es) * | 1996-02-15 | 2004-06-16 | Janssen Pharmaceutica N.V. | Uso de antagonistas del receptor 5ht4 para resolver los efectos gastrointestinales de los inhibidores de la reabsorcion de serotonina. |
| AU3290397A (en) | 1996-06-10 | 1998-01-07 | Depomed, Inc. | Gastric-retentive oral controlled drug delivery system with enhanced retention properties |
| US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
| SE9701304D0 (sv) * | 1997-04-09 | 1997-04-09 | Astra Pharma Prod | Compounds |
| PT975327E (pt) * | 1997-04-18 | 2003-11-28 | Janssen Pharmaceutica Nv | Uso de antagonistas de 5ht3 para estimular a lavagem intestinal |
| US6177879B1 (en) * | 1997-05-09 | 2001-01-23 | Honda Giken Kogyo Kabushiki Kaisha | Battery rental system and apparatus |
| US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
| WO1998055107A1 (en) | 1997-06-06 | 1998-12-10 | Depomed, Inc. | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs |
| DE19813661A1 (de) * | 1997-08-01 | 1999-02-04 | Solvay Pharm Gmbh | Gegen Racemisierung stabilisierte pharmazeutische Zubereitungen von Cilansetron |
| DE19734444A1 (de) * | 1997-08-08 | 1999-02-11 | Basf Ag | 3-Substituierte 3,4,5,7-Tetrahydro-pyrrolo(3',4':4,5) thieno (2,3-d) pyrimidin-Derivate, ihre Herstellung und Verwendung |
| US6156771A (en) * | 1997-08-28 | 2000-12-05 | Rubin; Walter | Method for alleviation of lower gastrointestinal disorders in a human patient |
| DK0901790T3 (da) * | 1997-09-16 | 2001-08-06 | Solvay Pharm Gmbh | Anvendelse af moxonidin til behandling af neuropatisk smerte |
| US6117879A (en) * | 1997-09-16 | 2000-09-12 | Solvay Pharmaceuticals Gmbh | Methods of using moxonidine to inhibit nociceptive pain |
| GB9721139D0 (en) * | 1997-10-07 | 1997-12-03 | Glaxo Group Ltd | Medicaments |
| US6211171B1 (en) * | 1998-05-19 | 2001-04-03 | Dalhousie University | Use of antidepressants for local analgesia |
| US6456458B1 (en) * | 1998-08-08 | 2002-09-24 | Nidec Corporation | Disk-drive motor rotating on a magnetically counterbalanced single hydrodynamic thrust bearing |
| US6476078B2 (en) * | 1999-08-11 | 2002-11-05 | Sepracor, Inc. | Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction |
| AU3422800A (en) * | 1999-02-18 | 2000-09-04 | Novartis Ag | Use of 5-ht3 receptor antagonists |
| WO2000048597A1 (en) * | 1999-02-18 | 2000-08-24 | Novartis Ag | Systemic use of 5-ht3 receptor antagonists against rheumatic inflammatory processes |
| US6362202B1 (en) * | 1999-03-02 | 2002-03-26 | Sepracor Inc. | Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists |
| US6353005B1 (en) * | 1999-03-02 | 2002-03-05 | Sepracor, Inc. | Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist |
| US6194382B1 (en) * | 1999-03-03 | 2001-02-27 | Albert Einstein College Of Medicine Of Yeshiva University | Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists |
| DE19911371A1 (de) * | 1999-03-15 | 2000-09-21 | Solvay Pharm Gmbh | Arzneimittel zur Behandlung von funktionellen Störungen und Erkrankungen der unteren Darmwege, insbesondere von damit einhergehenden abdominalen visceralen Schmerzen |
| US6448962B1 (en) | 1999-05-14 | 2002-09-10 | Three-Five Systems, Inc. | Safety timer to protect a display from fault conditions |
| DE19929197A1 (de) * | 1999-06-25 | 2000-12-28 | Novosis Pharma Ag | Transdermalsysteme zur Abgabe von 5-HT3-Rezeptor-Antagonisten und ihre Verwendung zur antiemitischen Behandlung |
| DE60022692T2 (de) * | 1999-07-01 | 2006-06-22 | Pharmacia & Upjohn Co. Llc, Kalamazoo | (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen |
| GB2355191A (en) * | 1999-10-12 | 2001-04-18 | Laxdale Ltd | Combination formulations for fatigue, head injury and strokes |
| HK1050135A1 (zh) | 1999-11-02 | 2003-06-13 | Depomed, Inc. | 用於促进将药物给予胃的饭後模式药理学诱导 |
| DE60123384T2 (de) | 2000-02-04 | 2007-08-02 | DepoMed, Inc., Menlo Park | Dosierungsform des typs "hülle und kern" mit einer wirkstofffreisetzung, die sich der nullten ordnung annähert |
| JP2001243182A (ja) | 2000-02-29 | 2001-09-07 | Nec Corp | サーバシステム及びＷｅｂコンテンツとサーバシステムとの連動方法 |
| US6488962B1 (en) | 2000-06-20 | 2002-12-03 | Depomed, Inc. | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
| US6566369B2 (en) * | 2000-07-26 | 2003-05-20 | Solvay Pharmaceuticals Gmbh | Medicament containing cilansetron for the treatment of non-obstipative male irritable bowel syndrome patients |
| US6451808B1 (en) | 2000-10-17 | 2002-09-17 | Depomed, Inc. | Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists |
| US6588708B2 (en) * | 2001-01-29 | 2003-07-08 | The Boeing Company | Spacecraft methods and structures for acquiring and determining power-safe attitudes |
| US20020107244A1 (en) * | 2001-02-02 | 2002-08-08 | Howard Harry R. | Combination treatment for depression |
| GB0112494D0 (en) * | 2001-05-22 | 2001-07-11 | Arachnova Therapeutics Ltd | New therapeutic use |
| US20040048874A1 (en) * | 2001-05-22 | 2004-03-11 | Bardsley Hazel Judith | New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine |
| GB0216027D0 (en) * | 2002-07-10 | 2002-08-21 | Arachnova Therapeutics Ltd | New therapeutic use |
| MXPA03011096A (es) | 2001-05-29 | 2004-12-06 | Depomed Dev Ltd | Metodo para el tratamiento de la enfermedad de reflujo gastroesofagico y la saturacion acida nocturna. |
| US6568519B2 (en) | 2001-08-10 | 2003-05-27 | Borgwarner, Inc. | Torque limiting chain sprocket assembly |
| US6475078B1 (en) * | 2001-10-09 | 2002-11-05 | Norb Borcherding | Air ventilating device |
| JP2005508358A (ja) | 2001-10-25 | 2005-03-31 | デポメド・インコーポレイテッド | 胃滞留型ロサルタン投与量を用いる治療方法 |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| CA2409552A1 (en) | 2001-10-25 | 2003-04-25 | Depomed, Inc. | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
| US20030091630A1 (en) | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
| TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
| US6458795B1 (en) * | 2001-11-15 | 2002-10-01 | University Of Florida | Method and composition for treatment of irritable bowel disease |
| DE60312474T2 (de) * | 2002-01-18 | 2007-12-06 | Aryx Therapeutics, Fremont | 5-ht3-rezeptorantagonisten und verwendungsverfahren |
| GB0202265D0 (en) * | 2002-01-31 | 2002-03-20 | Arachnova Therapeutics Ltd | New therapeutic use |
| US6682759B2 (en) | 2002-02-01 | 2004-01-27 | Depomed, Inc. | Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs |
| CA2479350A1 (en) * | 2002-03-15 | 2003-09-25 | Cypress Bioscience, Inc. | Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes |
| US20040032780A1 (en) * | 2002-04-08 | 2004-02-19 | Ehud Langberg | System and method for generating a clock signal in a communication system |
| CA2491836C (en) * | 2002-07-10 | 2011-01-25 | Arachnova Therapeutics Ltd. | 4-(2-fluorophenyl)-6-methyl-2(1-piperazinyl)thieno(2,3-d) pyrimidine in the treatment of functional bowel disorder |
| BR0313836A (pt) * | 2002-08-29 | 2005-06-21 | Arachnova Therapeutics Ltd | Novos usos terapêuticos de 4-(2-fluorofenil)-6-metil-2-(1-piperazinil)tieno[2,3-d]pi rimidina |
| JP2006516977A (ja) * | 2003-01-13 | 2006-07-13 | ダイノゲン ファーマシューティカルズ，インコーポレイテッド | 悪心、嘔吐、レッチング、またはそれらの任意の組み合わせの治療方法 |
| MXPA05007381A (es) * | 2003-01-13 | 2006-02-10 | Dynogen Pharmaceuticals Inc | Metodo para el tratamiento de transtornos funcionales del intestino. |
-
2004
- 2004-01-13 MX MXPA05007381A patent/MXPA05007381A/es not_active Application Discontinuation
- 2004-01-13 NZ NZ541008A patent/NZ541008A/en unknown
- 2004-01-13 KR KR1020057012930A patent/KR20050111318A/ko not_active Withdrawn
- 2004-01-13 JP JP2006500936A patent/JP2006516976A/ja not_active Ceased
- 2004-01-13 CN CNB2004800042278A patent/CN100353946C/zh not_active Expired - Fee Related
- 2004-01-13 BR BR0406749-5A patent/BRPI0406749A/pt not_active IP Right Cessation
- 2004-01-13 WO PCT/US2004/000807 patent/WO2004062623A2/en not_active Ceased
- 2004-01-13 EP EP10075488A patent/EP2286817A3/en not_active Withdrawn
- 2004-01-13 CA CA002512983A patent/CA2512983A1/en not_active Abandoned
- 2004-01-13 US US10/757,364 patent/US20040147509A1/en not_active Abandoned
- 2004-01-13 AU AU2004204825A patent/AU2004204825B2/en not_active Ceased
- 2004-01-13 PL PL378367A patent/PL378367A1/pl not_active Application Discontinuation
- 2004-01-13 EP EP04701811A patent/EP1558081A4/en not_active Withdrawn
- 2004-05-03 US US10/838,789 patent/US20040254168A1/en not_active Abandoned
- 2004-05-07 US US10/841,319 patent/US20040259862A1/en not_active Abandoned
- 2004-05-07 US US10/841,317 patent/US20040254169A1/en not_active Abandoned
- 2004-05-07 US US10/841,318 patent/US20040254170A1/en not_active Abandoned
- 2004-06-11 US US10/866,593 patent/US20050032780A1/en not_active Abandoned
-
2005
- 2005-04-29 US US11/119,357 patent/US20050192270A1/en not_active Abandoned
- 2005-07-20 ZA ZA200505817A patent/ZA200505817B/en unknown
-
2006
- 2006-05-26 US US11/441,905 patent/US20060217391A1/en not_active Abandoned
-
2011
- 2011-03-18 JP JP2011061194A patent/JP2011157372A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006516976A5 (https=) | ||
| JP2006522144A5 (https=) | ||
| TN2012000139A1 (en) | Cgrp receptor antagonists | |
| JP2006516977A5 (https=) | ||
| WO2006023460A3 (en) | COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | |
| BR0215348A (pt) | Derivados de carbamato de 1-alquil-1-azoniabiciclo[2-2]octano e uso destes como antagonistas do receptor muscarìnico | |
| WO2009126530A3 (en) | Piperidine derivatives as cgrp receptor antagonists | |
| US20080139591A1 (en) | CGRP Antagonists | |
| ES2476391T3 (es) | Agentes moduladores de receptor de calcio | |
| EA201270751A1 (ru) | Антагонист рецептора cgrp | |
| JP2009533343A5 (https=) | ||
| MX2009006319A (es) | Derivados de 5-[4-(azetidin-3-iloxi)-fenil] -2-fenil-5h tiazolo [5,4-c] piridin-4-ona y su uso como antagonistas del receptor de mch. | |
| NO20084603L (no) | Dialkylfenylforbindelser som har beta2 adrenergisk reseptoragonist- og muskarin reseptoragonistaktivitet | |
| JP2010155827A5 (https=) | ||
| WO2013042135A8 (en) | Heteroaryl compounds as 5-ht4 receptor ligands | |
| MX2010012189A (es) | Derivados de quinuclidina como antagonistas del receptor m3 muscarinico. | |
| BR112020022340A2 (pt) | benzamidas substituídas por 1,3-tiazol-2-il para o tratamento de doenças associadas com sensibilização de fibras nervosas | |
| RU2009133258A (ru) | Гетероциклические производные в качестве ингибиторов мускариновых рецепторов типа мз | |
| MX2012001160A (es) | Agonistas del receptor de esfingosina-1-fosfato. | |
| EA201070916A1 (ru) | Двойные фармакофоры - pde4-мускариновые антагонисты | |
| RU2011120347A (ru) | Способ лечения легочной артериальной гипертензии | |
| JP2015524828A5 (https=) | ||
| IL205231A0 (en) | Amino arylsulfonamide compounds and their use as 5 - ht6 ligands | |
| EA200970554A1 (ru) | 4-(гетероциклил)алкил-n-(арилсульфонил)индолсоединения и их применение в качестве 5-нтлигандов | |
| WO2009093206A3 (ru) | 3-CУЛЬФOHИЛ-ПИPAЗOЛO[1,5-a]ПИPИMИДИHЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |